{"nctId":"NCT00905268","briefTitle":"A Study of Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia (FRDA) Patients","startDateStruct":{"date":"2006-04"},"conditions":["Friedreich's Ataxia"],"count":232,"armGroups":[{"label":"Group A: Idebenone","type":"EXPERIMENTAL","interventionNames":["Drug: idebenone"]},{"label":"Group B: Idebenone","type":"EXPERIMENTAL","interventionNames":["Drug: idebenone"]},{"label":"C: Idebenone","type":"EXPERIMENTAL","interventionNames":["Drug: idebenone"]},{"label":"D: Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"idebenone","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Documented diagnosis of FRDA with confirmed FRDA mutations\n* Patients 8 years of age or older at baseline\n* Patients with body weight â‰¥ 25kg\n* Patients who in the opinion of the investigator are able to comply with the requirements of the study, including swallowing the medication\n* Negative urine pregnancy test at screening and at baseline (women of childbearing potential)\n\nExclusion Criteria:\n\n* Treatment with idebenone or Coenzyme Q10 within the past 1 month\n* Pregnancy and/or breast-feeding\n* Clinically significant abnormalities of clinical haematology or biochemistry including, but not limited to, elevations greater than 1.5 times the upper limit of normal of SGOT, SGPT, or creatinine\n* Past or present history of abuse of drugs or alcohol","healthyVolunteers":false,"sex":"ALL","minimumAge":"8 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Absolute Change in International Cooperative Ataxia Rating Scale (ICARS) Scores From Baseline Assessment to Week 52","description":"The International Cooperative Ataxia Rating Scale (ICARS) is a commonly used evaluation and is composed of four clinical sub-scores involving the following: posture and gait, limb coordination, speech and oculomotor function.The ICARS score is the total sum of the sub scores and ranges from 0 to 100, with 100 indicative of the most severely affected outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"5.85"},{"groupId":"OG001","value":"1.7","spread":"6.64"},{"groupId":"OG002","value":"1.2","spread":"5.22"},{"groupId":"OG003","value":"1.1","spread":"6.76"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Friedreich's Ataxia Rating Scale (FARS) Scores From Baseline Assessment to Week 52","description":"The Friedreich Ataxia Rating Scale (FARS) is made up of a measure of ataxia, and activities of daily living subscale and a neurological subscale. The scores from the three subscales are added to generate a total score ranging from 0 to 159, with a higher score indicating a greater level of disability.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"7.19"},{"groupId":"OG001","value":"1.2","spread":"5.24"},{"groupId":"OG002","value":"1.4","spread":"5.60"},{"groupId":"OG003","value":"0.9","spread":"6.77"}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients Improving (Responding) on ICARS by a Clinically Relevant Margin","description":"The International Cooperative Ataxia Rating Scale (ICARS) is a commonly used evaluation and is composed of four clinical sub-scores involving the following: posture and gait, limb coordination, speech and oculomotor function.The ICARS score is the total sum of the sub scores and ranges from 0 to 100, with 100 indicative of the most severely affected outcome.\n\nICARS Responder Analysis at Week 52: Percentage of subjects Improving by 2.5 Points or More.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.2","spread":null},{"groupId":"OG001","value":"23.6","spread":null},{"groupId":"OG002","value":"23.7","spread":null},{"groupId":"OG003","value":"31","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients Improving on Left Ventricular Peak Systolic Strain Rate or Showing a Reduction in Left Ventricular Mass Index (LVMI) With no Worsening in Strain Rate","description":"(In the statistical analysis sub-population presenting with cardiac involvement as defined by the FRDA cardiomyopathy criteria)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"51.4","spread":null},{"groupId":"OG002","value":"30.3","spread":null},{"groupId":"OG003","value":"44.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Peak Systolic Strain Rate From Baseline to Week 52","description":"Mean Change of Peak systolic longitudinal strain rate (PSLSR) from Baseline to Week 52 in subjects with cardiac involvement (FRDA-CM criteria), where positive value in PSLSR is a deterioration and negative value an improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.007","spread":"0.220"},{"groupId":"OG001","value":"-0.004","spread":"0.265"},{"groupId":"OG002","value":"0.085","spread":"0.227"},{"groupId":"OG003","value":"0.024","spread":"0.192"}]}]}]},{"type":"SECONDARY","title":"Change in Peak Workload From Baseline to Week 52","description":"Assessed by a modified exercise test, in a subset of patients able to undertake this.\n\nWpeak has been calculated from the following formula: Workload last fully completed stage + (seconds completed in last stage / 60 \\* (4 \\[if arm ergonometry\\] or 10 \\[if leg ergonometry\\])).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.15","spread":"16.362"},{"groupId":"OG001","value":"-7.41","spread":"34.499"},{"groupId":"OG002","value":"-6.91","spread":"20.179"},{"groupId":"OG003","value":"-1.54","spread":"16.509"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":57},"commonTop":["nasopharyngitis","headache","diarrhea","cough","oropharyngeal pain"]}}}